FDA Warns Anti-Malaria Drug Users About Psychiatric Side Effects
The Food and Drug Administration is affixing a new warning label to an anti-malaria medication called mefloquine hydrochloride. Previously going by the name Lariam, the product can lead the user to experience psychiatric or neurologic issues. For instance, the user could face anxiety, hallucinations, depression, ear ringing, or dizziness accompanied by balance issues. Unfortunately, this type of adversity could be permanent or last for years. As a result, the Medication Guides for this drug will now contain these new warnings and the labels themselves will obtain a new boxed warning. Persons experiencing side effects should speak with their doctors, who can recommend an alternate therapy or advise the discontinuation of the medication.
For more about the new warnings, follow this link.